脊柱关节炎的生物疗法。
Biological therapies for spondyloarthritis.
作者信息
Bruner Vincenzo, Atteno Mariangela, Spanò Angelo, Scarpa Raffaele, Peluso Rosario
机构信息
Rheumatology Research Unit, Department of Clinical Medicine and Surgery, University Federico II, Naples, Italy.
Rheumatology Research Unit, Department of Clinical Medicine and Surgery, University Federico II, via Sergio Pansini 5, 80131 Naples, Italy.
出版信息
Ther Adv Musculoskelet Dis. 2014 Jun;6(3):92-101. doi: 10.1177/1759720X14535512.
Abstract
Biological therapies and new imaging techniques have changed the therapeutic and diagnostic approach to spondyloarthritis. In patients with axial spondyloarthritis, tumor necrosis factor α (TNFα) inhibitor treatment is currently the only effective therapy in patients for whom conventional therapy with nonsteroidal anti-inflammatory drugs (NSAIDs) has failed. TNFα inhibitor treatment is more effective in preventing articular damage in peripheral joints than in axial ones. It is important to treat patients at an early stage of disease to reduce disease progression; moreover it is necessary to identify causes of therapy inefficacy in preventing joint damage in the axial subset.
摘要
生物疗法和新的成像技术改变了脊柱关节炎的治疗和诊断方法。在轴性脊柱关节炎患者中，肿瘤坏死因子α（TNFα）抑制剂治疗目前是传统非甾体抗炎药（NSAIDs）治疗失败患者的唯一有效疗法。TNFα抑制剂治疗在预防外周关节的关节损伤方面比在轴性关节更有效。在疾病早期治疗患者以减少疾病进展很重要；此外，有必要确定在预防轴性子集中关节损伤方面治疗无效的原因。
相似文献
1
Biological therapies for spondyloarthritis.脊柱关节炎的生物疗法。
Ther Adv Musculoskelet Dis. 2014 Jun;6(3):92-101. doi: 10.1177/1759720X14535512.
2
Pharmacological treatment of spondyloarthritis: exploring the effectiveness of nonsteroidal anti-inflammatory drugs, traditional disease-modifying antirheumatic drugs and biological therapies.脊柱关节炎的药物治疗：探索非甾体抗炎药、传统改善病情抗风湿药及生物疗法的有效性。
Ther Adv Chronic Dis. 2015 Nov;6(6):328-38. doi: 10.1177/2040622315608647.
3
Treatment Failure in Axial Spondyloarthritis: Insights for a Standardized Definition.治疗失败的中轴型脊柱关节炎：标准化定义的见解。
Adv Ther. 2022 Apr;39(4):1490-1501. doi: 10.1007/s12325-022-02064-x. Epub 2022 Feb 24.
4
Advances in the treatment of uveitis in patients with spondyloarthritis - is it the time for biologic therapy?脊柱关节炎患者葡萄膜炎治疗的进展——是时候采用生物疗法了吗？
Rom J Ophthalmol. 2018 Apr-Jun;62(2):114-122.
5
Axial spondyloarthritis.中轴型脊柱关节炎。
Nat Rev Dis Primers. 2015 Jul 9;1:15013. doi: 10.1038/nrdp.2015.13.
6
Impact of biological therapy on spondyloarthritis.生物疗法对脊柱关节炎的影响。
Eur J Clin Pharmacol. 2014 Sep;70(9):1021-7. doi: 10.1007/s00228-014-1706-x. Epub 2014 Jun 10.
7
Seropositive Neuromyelitis Optica in a Case of Undiagnosed Ankylosing Spondylitis: A Neuro-Rheumatological Conundrum.未确诊的强直性脊柱炎病例中的血清阳性视神经脊髓炎：一个神经风湿病学难题
Qatar Med J. 2022 Jul 7;2022(3):29. doi: 10.5339/qmj.2022.29. eCollection 2022.
8
Biologic therapies in the spondyloarthritis: new opportunities, new challenges.脊柱关节炎的生物治疗：新机遇，新挑战。
Curr Opin Rheumatol. 2003 Jul;15(4):394-407. doi: 10.1097/00002281-200307000-00005.
9
[Axial spondyloarthritis].[轴性脊柱关节炎]
Vnitr Lek. 2018 Spring;64(2):108-116.
10
Emerging treatment options for spondyloarthritis.新兴的脊柱关节炎治疗选择。
Best Pract Res Clin Rheumatol. 2018 Jun;32(3):472-484. doi: 10.1016/j.berh.2019.01.014. Epub 2019 Feb 21.
引用本文的文献
1
Difficult-to-Treat Spondyloarthritis in Morocco: A Real-World Study.摩洛哥难治性脊柱关节炎：一项真实世界研究。
Mediterr J Rheumatol. 2024 Dec 31;35(Suppl 3):549-556. doi: 10.31138/mjr.290124.dtt. eCollection 2024 Dec.
2
F-FDG positron emission tomography as a marker of disease activity and treatment response in ankylosing spondylitis and psoriatic arthritis.氟代脱氧葡萄糖正电子发射断层扫描作为强直性脊柱炎和银屑病关节炎疾病活动和治疗反应的标志物。
Sci Rep. 2024 Aug 28;14(1):19907. doi: 10.1038/s41598-024-60669-4.
3
Analysis of gene expression profiles and protein-protein interaction networks in multiple tissues of systemic sclerosis.系统性硬皮病多组织中基因表达谱和蛋白质-蛋白质相互作用网络分析。
BMC Med Genomics. 2019 Dec 27;12(1):199. doi: 10.1186/s12920-019-0632-2.
4
Disease-Modifying Effects of Long-Term and Continuous Use of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) in Spondyloarthritis.长期持续使用非甾体抗炎药（NSAIDs）对脊柱关节炎的病情改善作用
Adv Pharmacol Sci. 2019 Jan 29;2019:5324170. doi: 10.1155/2019/5324170. eCollection 2019.
5
Patient Concerns and Perceptions Regarding Biologic Therapies in Ankylosing Spondylitis: Insights From a Large-Scale Survey of Social Media Platforms.患者对强直性脊柱炎生物治疗的关注和看法：来自社交媒体平台的大规模调查洞察。
Arthritis Care Res (Hoboken). 2019 Feb;71(2):323-330. doi: 10.1002/acr.23600.
6
Medical Treatment of Ankylosing Spondylitis.强直性脊柱炎的医学治疗
Hip Pelvis. 2014 Sep;26(3):129-35. doi: 10.5371/hp.2014.26.3.129. Epub 2014 Sep 29.
7
Pharmacological treatment of spondyloarthritis: exploring the effectiveness of nonsteroidal anti-inflammatory drugs, traditional disease-modifying antirheumatic drugs and biological therapies.脊柱关节炎的药物治疗：探索非甾体抗炎药、传统改善病情抗风湿药及生物疗法的有效性。
Ther Adv Chronic Dis. 2015 Nov;6(6):328-38. doi: 10.1177/2040622315608647.
8
Safety Profile of Certolizumab Pegol in Patients with Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-Analysis.聚乙二醇化赛妥珠单抗在免疫介导的炎症性疾病患者中的安全性概况：一项系统评价和荟萃分析。
Drug Saf. 2015 Oct;38(10):869-88. doi: 10.1007/s40264-015-0336-2.
9
Management of arthropathy in inflammatory bowel diseases.炎症性肠病关节病的管理
Ther Adv Chronic Dis. 2015 Mar;6(2):65-77. doi: 10.1177/2040622314563929.
本文引用的文献
1
Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN).托珠单抗治疗强直性脊柱炎：一项II期随机双盲安慰剂对照研究（ALIGN）的结果
Ann Rheum Dis. 2015 Jun;74(6):1051-7. doi: 10.1136/annrheumdis-2013-204963. Epub 2014 Feb 18.
2
Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS).乌司奴单抗治疗活动期强直性脊柱炎患者的 28 周前瞻性开放标签概念验证研究（TOPAS）结果。
Ann Rheum Dis. 2014 May;73(5):817-23. doi: 10.1136/annrheumdis-2013-204248. Epub 2014 Jan 3.
3
Methotrexate in psoriatic arthritis.甲氨蝶呤治疗银屑病关节炎。
Bull Hosp Jt Dis (2013). 2013;71 Suppl 1:S41-5.
4
Certolizumab pegol in axial spondyloarthritis.培塞利珠单抗治疗中轴型脊柱关节炎。
Expert Rev Clin Immunol. 2013 Dec;9(12):1161-72. doi: 10.1586/1744666X.2013.858859.
5
Long-term treatment with golimumab for severe uveitis.使用戈利木单抗长期治疗严重葡萄膜炎。
Ocul Immunol Inflamm. 2014 Apr;22(2):90-5. doi: 10.3109/09273948.2013.844265. Epub 2013 Oct 21.
6
Ustekinumab in the treatment of psoriatic arthritis: latest findings and clinical potential.乌司奴单抗治疗银屑病关节炎：最新研究发现与临床应用潜力。
Ther Adv Musculoskelet Dis. 2013 Oct;5(5):277-85. doi: 10.1177/1759720X13501021.
7
Adalimumab for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis - a five-year update.阿达木单抗治疗强直性脊柱炎和非放射性轴性脊柱关节炎 - 五年更新。
Expert Opin Biol Ther. 2013 Nov;13(11):1599-611. doi: 10.1517/14712598.2013.839653. Epub 2013 Sep 27.
8
Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial.抗白介素-17A 单克隆抗体司库奇尤单抗治疗强直性脊柱炎：一项随机、双盲、安慰剂对照试验。
Lancet. 2013 Nov 23;382(9906):1705-13. doi: 10.1016/S0140-6736(13)61134-4. Epub 2013 Sep 13.
9
Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study.培塞丽珠单抗治疗包括强直性脊柱炎在内的中轴型脊柱关节炎的体征和症状的疗效：一项双盲随机安慰剂对照 3 期研究的 24 周结果。
Ann Rheum Dis. 2014 Jan;73(1):39-47. doi: 10.1136/annrheumdis-2013-204231. Epub 2013 Sep 6.
10
Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol.不同插补方法对银屑病关节炎患者影像学进展评估的影响：培塞利珠单抗治疗银屑病关节炎 24 周、III 期、双盲、安慰剂对照研究的结果。
Ann Rheum Dis. 2014 Jan;73(1):233-7. doi: 10.1136/annrheumdis-2013-203697. Epub 2013 Aug 13.
Zotero 插件